Management overview for systemic lupus erythematosus (SLE) in children and adolescents

Trindade, 2021Groot, 2017

Note: All children and adolescents diagnosed with systemic lupus erythematosus (SLE) should be initially managed by a paediatric rheumatologist.

All children and adolescents diagnosed with systemic lupus erythematosus (SLE) should be initially managed by a paediatric rheumatologist. Ideally, management for paediatric SLE should comprise a multidisciplinary approach with specialist input. The principles of management for children and adolescents are usually the same as managing SLE in adults; see Management overview for SLE in adults for more detailed discussion.

Pharmacological management for SLE depends on the organ(s) involved and the severity of inflammation. Hydroxychloroquine is the first-line drug recommended for all people with SLEGroot, 2017. Many children and adolescents require combination treatment with systemic corticosteroids and other immunomodulatory drugs, in addition to oral hydroxychloroquine.

Note: Urgently refer any child or adolescent with severe organ- or life-threatening features of SLE to a specialist centre for management.

Urgently refer any child or adolescent with severe organ- or life-threatening features of SLE to a specialist centre, because immunomodulatory drugs are usually required.

For advice about reproductive health (particularly contraception) in people with SLE, see Reproductive health in people with SLE.